











[Back to Search Results](#)

-  [Description](#)
-  [Details](#)
-  [Sub-Projects](#)
-  [Publications](#)
-  [Patents](#)
-  [Outcomes](#)
-  [Clinical Studies](#)
-  [News and More](#)
-  [History](#)
-  [Similar Projects](#)

Novel Influenza nano vaccines for broad cross protection

Project Number	Contact PI/Project Leader	Awardee Organization
5R01AI101047-08	WANG, BAOZHONG	GEORGIA STATE UNIVERSITY

 Share ▼

Description

Abstract Text

SUMMARY Influenza is a major public health risk. The current seasonal influenza vaccine is effective against closely matched viruses in healthy adults, but it cannot prevent the outbreaks of epidemics or pandemics because influenza viruses mutate frequently and zoonotic strains can jump the species barrier into humans. Other disadvantages of the seasonal influenza vaccine include the need to produce new vaccines every season, the uncertainty in selecting vaccine strains, and the compromised efficacy for mismatched viruses. A novel generation of influenza vaccines, termed universal influenza vaccines, will overcome these challenges. In the previous grant period, we have produced layered protein nanoparticles (nanoclusters) from conserved HA stalk antigens and the M2 protein ectodomain of influenza A. Nanocluster immunizations induced cross protection against viruses from both phylogenic groups of influenza A, including **pandemic-potential** avian strains. Both influenza A and influenza B cause influenza epidemics in humans. In this proposal, we propose to construct a multivalent layered nanocluster formulation composed of newly designed antigenic proteins from both influenza A and influenza B as a universal influenza vaccine. The new vaccine will induce broad cross- protection against both influenza types. We have three specific aims: Aim 1. To design and construct conserved antigens from influenza A and B, fabricate nanoclusters from these and previously designed antigenic proteins, and characterize these new nanoclusters. We will optimize the orchestration, composition, and stability of these nanoclusters for the physiologically-activated release of free antigenic proteins, antigen-processing and presentation after the uptake by dendritic cells, distribution of these nanoclusters to draining lymph nodes, and induction of strong antigen-specific immune responses in mice. Aim 2. To test whether these layered nanoclusters or an optimal combination will induce broadly reactive immune responses and whether the immunity will grant cross-protection against viruses spanning both influenza A and influenza B in mice. Aim 3. To test whether the leading multivalent nanocluster combinations will induce robust immune responses which confer broad cross-protection in ferrets. Overall, our research will develop a broadly cross-protective universal influenza vaccine.

Public Health Relevance Statement











Narrative: Influenza is the leading cause of death by infection. We will develop a protein nanoparticle universal influenza vaccine composed of newly designed influenza antigens from both influenza A and influenza B to induce broadly reactive immunity. The implementation and success of the project will improve public health by granting broad cross-protection against both influenza epidemics and pandemics.

Project Terms


Adaptive Immune System		Adult	Animal Model	Antibody titer measurement		
Antigen Presentation		Antigen Presentation Pathway		Antigen-Presenting Cells		
Antigens	Birds	Cause of Death		Chimeric Proteins	Dendritic Cells	
Disadvantaged	Disease Outbreaks		Drug Delivery Systems		Epidemic	Ethanol
Ferrets	Filtration	Formulation	Generations	Genes	Grant	Head
Hemagglutinin		Human	Immune	Immune response		Immunity
Immunization		Immunize	Infection	Inflammation	Influenza	
Influenza A virus		Influenza B Virus		Innate Immune Response		Intramuscular
Thank you for your feedback!						

Thank you for your feedback!

[Back to Search Results](#)

-  [Description](#)
-  [Details](#)
-  [Sub-Projects](#)
-  [Publications](#)
-  [Patents](#)
-  [Outcomes](#)
-  [Clinical Studies](#)
-  [News and More](#)
-  [History](#)
-  [Similar Projects](#)

Novel Influenza nano vaccines for broad cross protection

Project Number 5R01AI101047-08		Contact PI/Project Leader WANG, BAOZHONG		Awardee Organization GEORGIA STATE UNIVERSITY	
Contact PI/Project Leader		Contact PI		Program Official	
Leader		Not Applicable		Name	
Name				GORDON, JENNIFER L	
WANG, BAOZHONG 				Contact	
Title				jennifer.gordon2@nih.gov	
ASSOCIATE PROFESSOR					
Contact					
bwang3@emory.edu					
Organization					
Name		Department Type		State Code	
GEORGIA STATE UNIVERSITY		MISCELLANEOUS		GA	
City		Organization Type		Congressional District	
ATLANTA		ORGANIZED RESEARCH UNITS		05	
Country					
UNITED STATES (US)					
Other Information					
FOA		Administering Institutes or Centers		Project Start Date	15-May-2012
PA-18-859		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES		Project End Date	30-June-2024
Study Section		DUNS Number CFDA Code		Budget Start Date	01-July-2021
Vaccines Against Microbial Diseases Study Section[VMD]		837322494 855		Budget End Date	30-June-2022
Award Notice					
Fiscal Year	Date				
2021	21-June-2021				

Project Funding Information for 2021

Total Funding	Direct Costs	Indirect Costs
\$630,929	\$449,269	\$181,660
Year	Funding IC	
2021	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	
	\$630,929	

Sub Projects

No Sub Projects information available for 5R01AI101047-08











Publications

No Publications available for 5R01AI101047-08

Patents

Thank you for your feedback!

[Back to Search Results](#)

-  [Description](#)
-  [Details](#)
-  [Sub-Projects](#)
-  [Publications](#)
-  [Patents](#)
-  [Outcomes](#)
-  [Clinical Studies](#)
-  [News and More](#)
-  [History](#)
-  [Similar Projects](#)

Novel Influenza nano vaccines for broad cross protection

Project Number	Contact PI/Project Leader	Awardee Organization
5R01AI101047-08	WANG, BAOZHONG	GEORGIA STATE UNIVERSITY

The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

No Outcomes available for 5R01AI101047-08

Clinical Studies

No Clinical Studies information available for 5R01AI101047-08

News and More

Related News Releases

No news release information available for 5R01AI101047-08

History

No Historical information available for 5R01AI101047-08

Similar Projects

No Similar Projects information available for 5R01AI101047-08

Thank you for your feedback!